Literature DB >> 25266571

Prostate cancer: predicting resistance-AR-V7 is a potential biomarker.

Louise Stone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25266571     DOI： 10.1038/nrurol.2014.272

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245
  1 in total
  1 in total

1.  Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.

Authors:  Yangyang Han; Weiwei Huang; Jiakuan Liu; Dandan Liu; Yangyan Cui; Ruimin Huang; Jun Yan; Ming Lei
Journal:  Theranostics       Date:  2017-04-20       Impact factor: 11.556
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.